Journal of Neurology

, Volume 252, Supplement 1, pp i1–i6

Intravenous immunoglobulin in neurological disorders: a mechanistic perspective

  • Namita Misra
  • Jagadeesh Bayry
  • Amal Ephrem
  • Suryasarathi Dasgupta
  • Sandrine Delignat
  • Jean-Paul Duong Van Huyen
  • Fabienne Prost
  • Sebastien Lacroix-Desmazes
  • Antonino Nicoletti
  • Michel D. Kazatchkine
  • Srini V. Kaveri
Article

DOI: 10.1007/s00415-005-1102-7

Cite this article as:
Misra, N., Bayry, J., Ephrem, A. et al. J Neurol (2005) 252(Suppl 1): i1. doi:10.1007/s00415-005-1102-7

Abstract

Intravenous immunoglobulin (IVIg) has been used in the treatment of primary and secondary antibody deficiencies for over 25 years. It is a safe preparation with no long-term side effects. IVIg was first demonstrated to be effective in autoimmune disorders, two decades ago, in the treatment of acute immune thrombocytopenia. Since then, the therapeutic efficacy of IVIg has been established in Guillain Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP),myasthenia gravis (MG), dermatomyositis (DM), Kawasaki syndrome and the prevention of graft-versus-host disease in recipients of allogeneic bone marrow transplants and reported in a large number of other autoimmune and systemic inflammatory conditions.

Key words

intravenous immunoglobulin neurological disorders mechanisms 

Copyright information

© Steinkopff Verlag 2005

Authors and Affiliations

  • Namita Misra
    • 2
  • Jagadeesh Bayry
    • 2
  • Amal Ephrem
    • 2
  • Suryasarathi Dasgupta
    • 2
  • Sandrine Delignat
    • 2
  • Jean-Paul Duong Van Huyen
    • 2
  • Fabienne Prost
    • 2
  • Sebastien Lacroix-Desmazes
    • 2
  • Antonino Nicoletti
    • 2
  • Michel D. Kazatchkine
    • 2
  • Srini V. Kaveri
    • 1
  1. 1.INSERM U681, Institut des CordeliersParisFrance
  2. 2.INSERM U681 and Université Pierre et Marie Curie Institut des CordeliersParisFrance